There were no previous descriptions for the fusions NAIP:OCLN, PDE1C:DNAJC6, KANSL1:ARL17B, FOXP2:CREM, and AHSA1:DLG3 in the context of prostate cancer. This evidence concerns the gene NAIP and prostate carcinoma.